32 results about "Mother cells" patented technology

The invention provides a mother battery piece, a battery piece, a preparation method of the mother battery piece and a photovoltaic module. The battery piece comprises a first semiconductor substrate; the first doped semiconductor layer is arranged in the central region; the isolation groove is formed in the first isolation area and surrounds the central area; wherein the side surface comprises a first sub-surface, and the first sub-surface is connected with the groove wall of the isolation groove; the tunneling passivation contact structure is at least arranged on the second surface; the first passivation layer at least covers the first doped semiconductor layer, the isolation groove and the first sub-surface; wherein the first sub-surface and the second surface are both provided with a plurality of square tower footing structures, the difference between the side length of the largest square tower footing structure on the first sub-surface and the side length of the largest square tower footing structure on the second surface is a first numerical value, and the first numerical value is smaller than or equal to 15 microns. The battery efficiency can be improved, and the manufacturing cost can be reduced.

The present invention relates to a medium composition for in vitro fertilization and / or in vitro culture comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, and a method using same. The compound or composition suppresses reactive oxygen species and lipid peroxidation in ovarian granulosa cells to preventing cytotoxicity and mitochondrial dysfunction caused by apoptosis and ferroptosis, leading to an improvement in the quality of aged oocytes, and to increase the developmental rate and blastocyst formation rate of pre-implantation embryos, thereby improving the efficiency of in vitro fertilization. In addition, treatment with the medium composition during the vitrification process of in vitro–fertilized embryos improves re-expansion and survival rates, thereby reducing structural and metabolic damage. Accordingly, the present invention can be advantageously applied to an assisted reproductive technology for treating infertility and subfertility, and in vitro fertilization and / or in vitro culture for improving the propagation efficiency of livestock.

This invention discloses an engineered CAR-T cell targeting HIF-1α and its application in tumor immunotherapy. The CAR-T cell expresses a chimeric antigen receptor regulated by the hypoxia-responsive element HRE promoter, with its extracellular domain specifically binding to HIF-1α and its intracellular domain employing the 4-1BB+CD3ζ signaling module. Simultaneously, through immune checkpoint knockout and cytokine / chemokine modification, it achieves hypoxia-dependent activation, anti-exhaustion, high infiltration, and strong killing effects. The CAR-T cells of this invention significantly improve the adaptability to the solid tumor microenvironment and therapeutic efficacy, reduce off-target toxicity, and can be used to prepare drugs for treating malignant tumors such as lung cancer, liver cancer, pancreatic cancer, colorectal cancer, and glioblastoma, possessing significant clinical translational value.

The present application relates to the technical field of biological medicine, and more particularly to a culture solution, a kit and an application for in-vitro maturation of aged oocytes. Through in-vitro experiments, the present application adds exogenous stromal cell-derived factor 1, establishes a culture system for in-vitro maturation of aged oocytes, and reveals the molecular mechanism of stromal cell-derived factor 1 playing a role through autophagy, thereby providing a new solution for improving the fertility of aged women and improving the success rate of assisted reproductive technology, and having important clinical application value.

The present application belongs to the technical field of biological medicine, and particularly relates to Hermetia illucens extract, an extraction method thereof and application thereof in preventing and treating tumors. The present application extracts polar components from Hermetia illucens powder, and the obtained Hermetia illucens extract has a significantly better inhibitory activity on the proliferation of Cal27 human tongue squamous cell carcinoma cells, Colo205 human colorectal cancer cells and U87 MG human brain astrocytoma cells than the Hermetia illucens powder without separation under the same mass concentration. In animal experiments, the Hermetia illucens extract can significantly prolong the survival cycle of MOC-1 tongue squamous cell carcinoma mice, and has a significantly better treatment effect than the Hermetia illucens powder and is close to the positive drug cisplatin.

We provide a 3D artificial kinetic chorodor scaffold. [Solution] A composition is provided comprising a three-dimensional artificial kinetochore scaffold comprising a unit complex containing NDC80 protein and NUF2 protein. The composition may be biodegradable or proteinaceous, and the number of unit complexes contained in the three-dimensional artificial kinetochore scaffold may be 10,000 to 50,000 or 20,000 to 40,000. The three-dimensional artificial kinetochore scaffold of this disclosure has the ability to align at the spindle equator during meiosis of an oocyte, for example. The three-dimensional artificial kinetochore scaffold of this disclosure can preferably be used, for example, to suppress premature chromosome segregation during meiosis of an oocyte.

The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates. These compounds are in the form of conjugates, where doxorubicin and sclareol are covalently linked by a linker in a 1:1 molar ratio. The hybrids have shown to possess anticancer properties and are effective in treating resistant cancer cells that have P-glycoprotein membrane transporter, responsible for resistance to doxorubicin. The hybrids have been tested on different types of cell lines, including human glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma. Also, a method for their preparation and their use in medical products or pharmaceutical preparations has been determined. The results of the study include the cytotoxic activity of single, combined, and conjugated compounds in pairs of sensitive and resistant cancer cells, with and without P-glycoprotein expression. The selectivity towards cancer cells was determined by comparing with commercially available normal human lung fibroblast cells. The study also investigated the nanoparticle nature of hybrid compounds, their intracellular localization and toxicity in vivo.

This invention discloses a method for verifying TBCB glioblastoma and cell proliferation, belonging to the fields of bioinformatics and tumor molecular biology. S1: Constructing a TBCB knockdown model and verifying its effectiveness; S2: Obtaining transcriptome data from the knockdown group and control group using RNA-seq; S3: Obtaining a set of DEGs through differential expression analysis; S4: Performing disease enrichment analysis based on DisGeNET to obtain significantly enriched disease entries and screening for GBM / glioma-related entries; S5: Verifying the expression differences and clinical relevance of TBCB and GBM based on public databases (one or more of GEO / TCGA / CGGA); S6: Conducting an EdU incorporation experiment in U87 cells to quantitatively verify the effect of TBCB knockdown on cell proliferation. The verification method of this invention is more directly disease-targeting: by using DisGeNET disease enrichment, the DEGs set is directly mapped to specific disease entries such as "glioma / glioma," avoiding a focus solely on pathway levels.

The present invention relates to microbial cells, including but not limited to aerobic bacteria cells and anaerobic bacteria cells, as well as yeast cells, and methods for producing the cells, feed additives and compositions comprising the cells, and uses involving administration of the cells to animals.

Embodiments of the disclosure encompass adoptive immunotherapy related to cells expressing multiple chimeric antigen receptors (CARs). In specific embodiments, T cells express a HER2-specific CAR, an IL13Rα2-specific CAR, and an EphA2-specific CAR. In particular embodiments, the cells are utilized for cancer treatment, including for glioblastoma.

The application relates to the field of super-low-temperature cryopreservation of mammalian oocytes, and particularly relates to application of miR-32 in improving the development capacity of pig immature oocytes after freezing. Pig immature oocytes are frozen and cultured in vitro, and mature oocytes which are cultured to expel the first polar body are incubated in transfection liquid containing a miR-32 nucleotide sequence for 2-6 hours; the pig immature oocytes are GV stage oocytes; and the miR-32 nucleotide sequence is shown in SEQ ID NO:1. It is found that miR-32 can be used as a key marker molecule of damage of vitrification oocytes, and by transfecting miR-32 mimics into the frozen oocytes, the early embryo development capacity of the oocytes can be improved, a new solution is provided for improving the maturation quality of the frozen oocytes, and various embryo biological technology researches are facilitated.

The application discloses a phenylalanine ammonia-lyase gene RkPAL , which is separated from red yeast (Rhodotorula rubra) Rhodosporidium kratochvilovae , has a nucleotide sequence as shown in SEQ ID NO:1, and encodes an amino acid sequence as shown in SEQ ID NO:2. The gene is connected with a carrier and is transferred into red yeast cells, and experimental results show that RkPAL overexpression of the gene can promote the red yeast to synthesize carotenoids and oil; and the application provides a reference for large-scale commercial production of carotenoids and oil.

Disclosed herein are genetically engineered yeast cells capable of producing xylitol, characterized by a deletion or disruption in a native gene encoding erythrose reductase having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with at least one of SEQ ID NOs: 292 and 295. The genetically engineered yeast cells may be further genetically engineered to overexpress native RPE enzyme, express exogenous XPDH enzyme, express exogenous XKS enzyme, express exogenous XDH enzyme, overexpress native X5PP enzyme, and / or express exogenous X5PP enzyme.

The application discloses a DREB transcription factor CtDREB1B of safflower and application thereof in positive regulation of drought and salt stress resistance of plants. The full-length nucleotide sequence of the gene CtDREB1B is shown as SEQ ID NO. 2, and the amino acid sequence of the encoded protein is shown as SEQ ID NO. 1. The application first clones the complete coding frame of the gene by RT-PCR, clones the gene into a pYES2 vector and transfers the gene into yeast, and finds that the pYES2::CtDREB1B yeast cells can still grow on SGR culture medium containing 1.5 M mannitol or 4 M NaCl. Then, the CtDREB1B gene is heterologously expressed into Arabidopsis thaliana. Overexpression of the CtDREB1B in the Arabidopsis thaliana can make the transgenic Arabidopsis thaliana exhibit a drought and salt tolerance phenotype, and the activities of protective enzymes such as SOD and POD are enhanced, and the expression amounts of stress resistance related genes such as AtABF3 and AtRD29A are up-regulated, indicating that the gene can simultaneously positively regulate drought and salt stress. Therefore, the gene can be applied to breeding of new plant stress resistance varieties, and in addition, the gene provides a new gene resource for plant stress resistance, and has important application prospects in breeding of salt-tolerant plants.

The invention provides a mother battery piece, a battery piece, a preparation method of the mother battery piece and a photovoltaic module. The battery piece comprises a first semiconductor substrate, the first semiconductor substrate comprises a first surface, a second surface and a side surface, the first surface and the second surface are oppositely arranged, the side surface is connected with the first surface and the second surface, and the first surface comprises a central region and a first isolation region arranged around the central region; the first doped semiconductor layer is arranged in the central region; the isolation groove is formed in the first isolation area and surrounds the central area; the tunneling passivation contact structure is at least arranged on the second surface; the first substrate doping layer is arranged on at least part of the side surface; the first passivation layer at least covers the first doped semiconductor layer, the isolation groove and the first substrate doped layer; the battery efficiency can be improved, and the manufacturing cost can be reduced.

Inventors determined that recombinant glioblastoma cell lines overexpressing αS- SETMAR (a stable form of S-SETMAR) exhibited a prolonged cell cycle from 27 to 37 hours that leads to a reduction in cell proliferation. The over-expression of αS-SETMAR revealed an unexpected role for this protein as it increased DNA quantity linked to chromosomal chaos, both in terms of chromosomes number (aneuploidy) and organization (chromoanagenesis). Finally, they have noted that αS-SETMAR over-expression makes cells more sensitive to stringent conditions for their survival, such as those used during chemotherapy or radiotherapy treatments. These data allow them to conclude that αS-SETMAR reduces cell proliferation, sensitizes cells to chromosomal chaos and irradiation-induced apoptosis, opening up the possibility of using αS-SETMAR as a therapeutic or prognosis protein. The present invention relates to a method for sensitizing glioblastoma cells to a classical treatment comprising a step of administrating an agonist of αS-SETMAR in a subject in need thereof.

Methods and systems to assess the viability of human oocytes for egg vitrification or cryopreservation process are disclosed herein. The method utilizes fluorescence lifetime imaging microscopy (FLIM) coupled with integrating an oocyte's morphological endpoints, such as shape and size, to assess and identify the viability in human oocytes. The method and system also use data analysis software capable of correlating PH values, FLIM data, and chromosomal health assessments to determine the viability of human oocytes.

The application discloses application of a detection reagent in detection of ZM fusion gene (PTPRZ1-MET fusion gene) positive secondary glioblastoma (sGBM), and belongs to the technical field of biological medicine, so as to solve the problems of the existing ZM fusion detection method, such as complex operation, poor specificity, and unsuitability for routine clinical detection. Based on high-throughput RNA sequencing and machine learning algorithm (XGBoost) analysis, it is found for the first time that the combined expression profile of three genes, MET, PCDHGA3 and FAM3C, can significantly distinguish ZM fusion positive and negative samples, and the diagnostic accuracy (AUC) is as high as 99.8%, with high sensitivity and specificity. The detection product of the application is suitable for paraffin-embedded (FFPE) pathological tissue samples and frozen samples, and can complete the detection in combination with mature platforms such as multiplex immunohistochemistry or high-throughput RNA sequencing, and has good sample compatibility and operation feasibility.

The present disclosure describes a unique viral peptide (VP) vaccine for preventing or treating viral diseases. The vaccine is produced synthetically and includes no production steps in biological cells (e.g. E. coli, CHO cells, yeast cells) that would require subsequent endotoxin assays / removal or viral clearance procedures. The hC peptide is synthesized separately from the VP, and following self-assembly of the hC, the VP is covalently coupled to form the VP-hC conjugate which can serve as a vaccine for preventing or treating viral diseases. The hC includes heptad repeats following a specific pattern. Optionally, the VP-hC conjugate further includes one or more T-cell epitopes at the N- and / or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions comprising immunogenic compositions including VP-hC conjugate.

Disclosed are methods for increasing the fertilization rate of an oocyte in a granulosa cell-oocyte complex, and / or the success rate of in-vitro fertilization by using mitochondrial therapies. Also disclosed are methods of identifying compounds for fertility treatment.

The application discloses a screening and detection method based on a nuclear male sterility gene of oil flax, and belongs to the technical field of molecular biology and plant breeding. The method comprises the following steps: performing single-cell transcriptome sequencing on anther tissues of oil flax flower buds in multiple periods of development, and identifying differentially expressed genes of tapetum cells and microsporocyte cell groups before meiosis; performing homologous alignment on the differentially expressed genes of the cell groups and an Arabidopsis thaliana nuclear male sterility gene set, and screening nuclear male sterility candidate genes of the oil flax; designing overlapping primer pairs for long fragment PCR amplification and sequencing according to the candidate genes, and obtaining sequence difference sites between sterile lines and fertile lines; designing a high-resolution melting curve detection primer group for amplification reaction according to the sequence difference sites, and distinguishing the genotypes of the sterile lines and the fertile lines according to the peak type difference of the melting curves.

Provided herein are genetically modified yeast cells that recombinantly express a gene encoding a mutant beta-lyase. Also provided are methods for producing fermentation products and methods for producing ethanol.

This invention relates to the field of biomedical technology, and more particularly to the use of a combination of RVX208 and temozolomide for the treatment of glioblastoma. It also relates to the use of RVX208 to resensitize temozolomide-resistant cancers to temozolomide treatment. The use of at least one of RVX208, a pharmaceutically acceptable salt of RVX208, a solvate of RVX208, a hydrate of RVX208, a polymorph of RVX208, an isomer of RVX208, a prodrug form of RVX208, and temozolomide in the preparation of a glioblastoma therapeutic agent. RVX208 inhibits the transcriptional activity of various genes related to cell cycle progression and proliferation maintenance by inhibiting BET family proteins or other target molecules, leading to cell cycle arrest, inhibition of cell proliferation, and induction of programmed cell death. RVX208 also interferes with the transcriptional expression of genes related to mitochondrial homeostasis regulation, resulting in a decrease in mitochondrial membrane potential and reduced ATP production, thus enabling RVX208 to disrupt mitochondrial function in GBM cells and produce a synergistic antitumor effect with temozolomide.

Viability of cancer cells (e.g., glioblastoma cells) can be reduced by applying an alternating electric field with a frequency between 100 and 500 kHz to the cancer cells for about 3-10 days and administering a checkpoint inhibitor to the cancer cells.